Hengrui Medicine And Hansoh Pharmaceutical To Set Up Pharmaceutical R&D Base
This article was originally published in PharmAsia News
Executive Summary
Jiangsu Hengrui Medicine and Jiangsu Hansoh Pharmaceutical recently began construction of their co-funded pharmaceutical industry park in Lianyungang Economic and Technological Development Zone. The two Jiangsu companies will jointly invest RMB 3 billion ($439 million) to build a U.S. and EU standards-compliant pharmaceutical formulation plant, office building, R&D center and auxiliary facilities. Covering an area of 40 hectares, the base will build workshops for formulations of solid, freeze-dried powder and injections, transfusion fluids, contrast agents and bioproducts. The RMB 1.2 billion ($175 million) phase I project is targeted to finish by 2011, while the entire project will be completed within five years. The two companies plan to launch five to six Class I new drugs of original IP rights in the next five years. (Click here for more - Chinese Language)
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.